A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

A federal judge has issued a temporary pause across all states on the new NIH order that caps “indirect costs” for research grants—a move designed to slash costs by $4 billion per year. | A federal ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving ...